Replies to post #380260 on Elite Pharmaceuticals Inc (ELTP)

[kayak_wench]

I need some help seeing how the article says skinny labels are O.K.
It seems to say the opposite to me.

1. A jury awarded GSK $235 million in 2017.
2. A judge then overturned the verdict,
3. the patent-focused U.S. Court of Appeals for the Federal Circuit reinstated 'it' in 2020, where 'it' is the award of $235 million to GSK for Teva using a skinny label
4. The supreme court said "no, we don't want to hear the case" the last decision saying Teva was wrong to use a skinny label stands
"The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication."

Teva (the generic drug company was unhappy

Teva, in its appeal, told the Supreme Court that the ruling would cause "havoc" and discourage the use of skinny labels, which it said are "extraordinarily common" and "save patients and the federal government billions."

Biden was unhappy for generic companies in general
President Joe Biden's administration also urged the Supreme Court to hear the case, arguing that the Federal Circuit's decision created "significant uncertainty" for generic drugmakers.

So again, how is this good news for Elite and how does this make skinny labels OK? Sounds to me that Elite has to find a way to cover everything the non-generic covers.